Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
India’s nationwide lockdown triggered by the coronavirus pandemic is hampering its Japan-bound exports of APIs and intermediates, which, if continued, could have an impact on the supply of final drug products, according to several API trading houses. India issued a…
To read the full story
Related Article
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





